Glucotoxicity inhibits cAMP-protein kinase A-potentiated glucose-stimulated insulin secretion in pancreatic β-cells

J Diabetes. 2015 May;7(3):378-85. doi: 10.1111/1753-0407.12185. Epub 2014 Sep 6.

Abstract

Background: The effect of incretin is markedly blunted in patients with type 2 diabetes (T2D), and this reduced effect of incretin is correlated with a diminished insulintropic potency of glucagon-like peptide-1 (GLP-1). We reported recently that GLP-1 potentiates glucose-stimulated insulin secretion (GSIS) mainly via activation of the cAMP-protein kinase A (PKA) signaling pathway in INS-1E cells under hyperglycemic conditions. In the present study, we further explored whether glucotoxicity impairs cAMP-PKA-mediated effects and its relevance to the reduced insulinotropic action of GLP-1 in hyperglycemia.

Methods: Mouse islets and INS-1E cells were cultured in 30 mmol/L glucose for 72 h. The effects of glucotoxicity on cAMP-PKA-linked pathways and its insulinotropic action were then evaluated.

Results: Chronic exposure of INS-1E cells and primary mouse islets to 30 mmol/L glucose almost abolished GSIS. The cAMP-elevating agent forskolin produced an approximate 1.9-fold increase in GSIS, significantly lower than that observed with 5.5 mmol/L glucose (~3.3-fold). Moreover, 72 h culture in the presence of 30 mmol/L glucose reduced forskolin-stimulated cAMP accumulation in β-cells. Notably, glucotoxicity reduced the expression and activity of PKA, as well as PKA-mediated effects. In contrast, glucotoxicity had no effect on the expression of Epac2, another cAMP effector.

Conclusions: Glucotoxicity-induced reductions in PKA and its signaling account, at least in part, for the decreased incretin effect under conditions of glucotoxicity.

Keywords: cAMP; glucagon-like peptide-1; glucotoxicity; insulin secretion; protein kinase A; 关键词:cAMP,胰高血糖素样肽-1,葡萄糖毒性,胰岛素分泌,PKA。.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blotting, Western
  • Cells, Cultured
  • Cyclic AMP / antagonists & inhibitors
  • Cyclic AMP / metabolism*
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Female
  • Glucose / toxicity*
  • Insulin / metabolism*
  • Insulin Secretion
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / metabolism*
  • Mice
  • Mice, Inbred C57BL
  • Sweetening Agents / toxicity*

Substances

  • Insulin
  • Sweetening Agents
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • Glucose